FRAMINGHAM (01/15/2004) - De Novo Pharmaceuticals Ltd. has abandoned in silico drug design to focus on commercializing proprietary discovery platforms. The company intends to collaborate with pharmaceutical and biotech firms that want to use De Novo platforms such as the chemical structure generator SkelGen. Closing its discovery labs resulted in job losses for half of the company's 48 employees.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.